Passage Bio Inc. (NASDAQ: PASG) is 51.80% higher on its value in year-to-date trading and has touched a low of $8.09 and a high of $38.23 in the current 52-week trading range. The PASG stock was last observed hovering at around $33.70 in the last trading session, with the day’s gains setting it 1.36% off its average median price target of $28.00 for the next 12 months. It is also -7.88% off the consensus price target high of $32.50 offered by 4 analysts, but current levels are -40.24% lower than the price target low of $25.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $35.06, the stock is 30.00% and 52.53% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.55 million and changing 4.04% at the moment leaves the stock 73.46% off its SMA200. The firm has a 50-day simple moving average (SMA 50) of $24.73 and a 200-day simple moving average (SMA200) of $20.21.
The stock witnessed a 37.27% gain in the last 1 month and extending the period to 3 months gives it a 128.63%, and is 16.81% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.30% over the week and 9.60% over the month.
Distance from 52-week low is 333.37% and -8.29% from its 52-week high.
Passage Bio Inc. (PASG) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Passage Bio Inc. (PASG) is a “Overweight”. 4 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Passage Bio Inc. is expected to release its quarterly report on 09/02/2020 and quarterly earnings per share for the current quarter are estimated at -$0.57.
Passage Bio Inc. (PASG) Top Institutional Holders
21 institutions hold shares in Passage Bio Inc. (PASG), with 8.74M shares held by insiders accounting for 19.27% while institutional investors hold 69.51% of the company’s shares. The shares outstanding are 45.35M, and float is at 17.10M with Short Float at 3.36%. Institutions hold 56.12% of the Float.
The top institutional shareholder in the company is Orbimed Advisors LLC. with over 6.96 million shares valued at $109.67 million. The investor’s holdings represent 15.35% of the PASG Shares outstanding. As of Mar 30, 2020, the second largest holder is Frazier Management LLC with 5.01 million shares valued at $78.9 million to account for 11.05% of the shares outstanding. The other top investors are FMR, LLC which holds 3.13 million shares representing 6.91% and valued at over $49.36 million, while New Leaf Venture Partners, L.l.c. holds 5.51% of the shares totaling 2.5 million with a market value of $39.34 million.
Passage Bio Inc. (PASG) Insider Activity
A total of 32 insider transactions have happened at Passage Bio Inc. (PASG) in the last six months, with sales accounting for 0 and purchases happening 32 times.